SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03521596

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance

Multicenter retrospective and prospective observational study including patients with WM or IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly sensitive techniques.

NCT03521596 Waldenstrom Macroglobulinemia
MeSH:Waldenstrom Macroglobulinemia
HPO:Monoclonal immunoglobulin M proteinemia

1 Interventions

Name: MRD and clonal evolution

Description: Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
Type: Other
Group Labels: 1

Patient enrolled


Primary Outcomes

Description: To demonstrate that the rate of mutations of MYD88 (L265P) and/or CXCR4 (S338X) detected in peripheral blood and/or urine show a negligible difference with the rate of mutations detected in bone marrow samples (BM, gold standard)

Measure: Rate of mutation

Time: 22 months

Time Perspective: Other

Cohort


There is one SNP

SNPs


1 L265P

To demonstrate that the rate of mutations of MYD88 (L265P) and/or CXCR4 (S338X) detected in peripheral blood and/or urine show a negligible difference with the rate of mutations detected in bone marrow samples (BM, gold standard). --- L265P ---



HPO Nodes


HPO: